ArticleCommunications medicine2025
Glioblastoma zebrafish Avatars guide therapeutic decisions in a patient with gliosarcoma: a case report.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma is the most common and lethal brain tumor. Therapeutic options after recurrence are scarce and with no agreement as to which treatment to offer. Also, no functional tests are currently in use to guide clinical decisions. As a result, patients often undergo multiple treatments, being exposed to toxicities and wasting valuable time.
methodsHere we report a case of a 37-year-old man with a left temporal glioblastoma (gliosarcoma subtype), who underwent several surgeries and treatments. Tumor DNA sequencing revealed no actionable mutations. At the second recurrence, brain MRI showed three new left-hemisphere nodular lesions, leading to a third surgery. However, twenty-days post-surgery the patient relapsed. Therapeutic options available for this patient were no longer well defined and 13 possible off-label options emerged. Fresh tumor samples were used to generate patient-derived zebrafish xenografts (zAvatars) to test the 13 options in combination with radiotherapy.
resultsPemetrexed, and Pemetrexed with Doxorubicin together with Radiotherapy, were both effective in inducing apoptosis. Due to toxicity concerns, the physician opted for the combination of radiotherapy and pemetrexed, with doxorubicin introduced later. The patient recovered and was stable for two months, consistent with the zAvatar prediction.
conclusionsThe rapid establishment of zAvatars from glioblastoma tumor samples allows for the testing of drug combinations and the tailoring of treatment in a personalized and timely manner. A future pipeline of tumor sequencing together with zAvatars testing, since the first surgery, may help manage patients more effectively, potentially improving their Progression free survival (PFS) and overall survival (OS).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.